Background: Although several studies have determined quality of life in patients with lung cancer, there is still little information about the use of generic questionnaires [e.g. the 36-item Short Form health survey (SF-36)] and utility questionnaires [e.g. the EuroQOL instrument (EQ-5D)] in...

The resources devoted to managing metastatic prostate cancer are enormous, yet little attention has been given to directly measuring the economic consequences of treatment alternatives. The purpose of this article was to evaluate the pharmacoeconomics of available treatments for metastatic...

The treatment of germ-cell tumours of the testis can be considered as a model for cancer management, representing public education, diagnosis and cure with long term follow-up. Psychosocial distress, fertility and secondary tumour induction can also be studied. The aetiology of this disease is...

In the US, 1 in 3 women and 1 in 2 men will be diagnosed with cancer at some point in their lives. More than 1.2 million individuals are diagnosed with cancer each year while it is estimated that 8.2 million Americans, alive today, have a history of cancer. Cancer diagnosis and treatment...

Ovarian cancer is the leading cause of death in women with gynaecological cancers. The most common type of ovarian cancer is epithelial ovarian cancer. Referred to as the `silent' killer, this disease is difficult to detect because of the lack of specific symptoms. The majority of women who have...

The aim of this paper was to conduct a critical systematic review of the available literature on the clinical and economic burden of bladder cancer in developed countries, with a focus on the cost effectiveness of interventions aimed at reducing that burden. Forty-four economic studies were...

Objective: To evaluate the potential cost savings of using sequential high dose chemotherapy (HDC), with granulocyte colony-stimulating factor (filgrastim) and stem cell support, rather than single course administration of HDC with bone marrow transplantation (BMT) or peripheral blood stem cell...

Whereas individual cost-effectiveness analyses of new agents for acute leukaemia should be performed in target populations, any meaningful pharmacoeconomic evaluation of treatment options for this condition should include the many types of costs and outcomes in unselected, representative groups...